Pharmacogenetics for IBD drug

Research Project

Project/Area Number	25860539
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Gastroenterology
Research Institution	Institute of Physical and Chemical Research
Principal Investigator	Urabe Yuji 国立研究開発法人理化学研究所, 統合生命医科学研究センター, 客員研究員 (10648033)
Project Period (FY)	2013-04-01 – 2016-03-31
Project Status	Completed (Fiscal Year 2015)
Budget Amount *help	¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000) Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000) Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000) Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywords	SNP / IBD / Pharmacogenetics / drug / 炎症性腸疾患 / 一塩基多型 / 薬理遺伝学
Outline of Final Research Achievements	Recently, the development of various new drugs for inflammatory bowel disease (IBD) has improved the rate of remission maintenance. Nevertheless, the methods for remission maintenance and/or permanent treatment for IBD are complicated according to the various types of IBD treatments available. The aim of this study was to clarify the genetic factors contributing to the treatment effect for IBD. Genomic DNA was extracted from approximately 600 IBD patients, and the single nucleotide polymorphisms (SNPs) of genes associated with the treatment effect of IBD drugs were determined using a multiplex polymerase chain reaction-based invader assay. We explored susceptibility genes for the effects of IBD drugs; however, did not discover any significant association of the SNPs tested with the effect of IBD drugs.